Occurrence of blaCMY-42 on an IncI1 plasmid in multidrug-resistant Escherichia coli from a tertiary referral hospital in India

Ingti, Birson; Saikia, Pranjit; Paul, Deepjyoti; Maurya, Anand Prakash; Dhar, Debadatta; Chakravarty, Atanu; Deshamukhya, Chandrayee; Bhattacharjee, Amitabha

doi:10.1016/j.jgar.2018.02.021

Cited by 12 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This variant had previously been isolated sporadically in few patients from China, India, Egypt and Spain [26–29] and also in urban water in India, confirming its presence in the environment of this country [30]. Very recently, a study reported a prevalence of 18% of CMY-42 in clinical samples from a tertiary referral hospital of India [31]. By comparing nucleotide sequence of CMY-42 to CMY-2, the difference of two amino-acids located in the omega loop of the enzyme confers an increasing resistance to third generation cephalosporins and to cefepime, usually spared by pAmpC [32].…”

Section: Discussionmentioning

confidence: 61%

Acquisition of plasmid-mediated cephalosporinase producing Enterobacteriaceae after a travel to the tropics

Lorme¹,

Maataoui²,

Rondinaud³

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

Travelers are at high risk of acquiring multi-drug resistant Enterobacteriaceae (MRE) while traveling abroad. Acquisition of extended spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) while traveling has been extensively described, but not that of plasmid-mediated cephalosporinase producing Enterobacteriaceae (pAmpC-E). Here, we characterized the pAmpC-E acquired in 574 French travelers to tropical areas enrolled in the VOYAG-R study. Among the 526 MRE isolated at return, 57 (10.8%) from 49 travelers were pAmpC-E. The acquisition rate of pAmpC-E was 8.5% (49/574) ranging from 12.8% (25/195) in Asia, 7.6% (14/184) in Latin America to 5.1% (10/195) in Africa. The highest acquisition rates were observed in Peru (21.9%), India (21.4%) and Vietnam (20%). The carriage of pAmpC-E decreased quickly after return with 92.5% of colonized travelers being negative at one month. Most enzymes were CMY types (96.5%, n = 55, only met in Escherichia coli), including 40 CMY-2 (70.2%), 12 CMY-42 (21.1%), 1 CMY-6 and two new CMY-2 variants. The remaining were two DHA observed in Klebsiella pneumoniae. CMY-2 producing strains were acquired worldwide whereas CMY-42, except for one, were all acquired in Asia. BlaCMY-2 genes were associated with different plasmid types, including IncI1 (45. 2%), IncF (10%), IncF-IncI (7.5%), IncA/C (5%) and IncR (2.5%) whereas blaCMY-42 were all associated with IncI1 plasmids. Even though the pAmpC-E acquisition rate was much lower than that of ESBL-E, it was significant, especially in Asia, showing that pAmpC-E, especially CMY-type producing E. coli have spread in the community settings of tropical regions.

show abstract

Section: Discussionmentioning

confidence: 61%

Acquisition of plasmid-mediated cephalosporinase producing Enterobacteriaceae after a travel to the tropics

Lorme¹,

Maataoui²,

Rondinaud³

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…The bla CMY-42 gene was detected on IncI1 plasmids, which was in harmony with Ingti et al (2018) that reported the propagation of bla CMY-42 on IncI1-type plasmids in E . coli ST5377, ST361 and ST672 collected in India between 2012 and 2013 [ 20 ]. Studying its genetic environment, we observed upstream of the bla CMY-42 the two genes previously reported by Singh et al (2018) [ 21 ]: blc and sugE encoding for an outer membrane lipoprotein and a drug efflux pump, respectively.…”

Section: Discussionmentioning

confidence: 99%

Molecular characterization of Carbapenem resistant Escherichia coli recovered from a tertiary hospital in Lebanon

et al. 2018

View full text Add to dashboard Cite

The emergence of carbapenem resistant Escherichia coli represents a serious public health concern. This study investigated the resistome, virulence, plasmids content and clonality of 27 carbapenem resistant E. coli isolated from 27 hospitalized patients at the American University of Beirut Medical Center (AUBMC) in Lebanon between 2012 and 2016. Whole-genome sequencing (WGS) data were used to identify resistance determinants. Multilocus sequence typing (MLST), pulsed field gel electrophoresis (PFGE), phylogenetic grouping and PCR-based replicon typing (PBRT) were also performed. The 27 isolates were distributed into 15 STs, of which ST405 (14.8%; n = 4) was the most prevalent. All of the 27 isolates were carbapenem resistant and 20 (74%) were extended-spectrum β-lactamase (ESBL) gene carriers. The predominant detected carbapenemases were blaOXA-48 (48.1%; n = 13) and blaOXA-181 (7.4%; n = 2), for the ESBLs it was blaCTX-M-15 (55.6%; n = 15) and blaCTX-M-24 (18.5%; n = 5), and for the AmpC-type β–lactamases, blaCMY-42 (40.7%; n = 11) and blaCMY-2 (3.7%; n = 1). Thirteen replicons were identified among the 27 E. coli isolates including: IncL/M, IncFIA, IncFIB, IncFII, IncI1, and IncX3. PFGE revealed a high genetic diversity with the 27 isolates being grouped in 21 different pulsotypes. SNPs analysis and PFGE showed a possible clonal dissemination of ST405, ST1284, ST354 and ST410 and the dominance of certain STs, monitoring of which could help in elucidating routes of transmission. This study represents the first WGS-based in depth analysis of the resistomes and mobilomes of carbapenem resistant E. coli in Lebanon.

show abstract

“…WGS analysis revealed that E. coli N1606 belonged to Sequence Type ST361 and to the O9:H30 serotype. The lineage in which E. coli ST361 belongs is not recognized so far as internationally widespread with very few reports either in human or animals, making it difficult to fully discuss and compare results from different epidemiological studies [ 22 , 23 , 24 , 25 ]. Very recently, an E. coli ST361 harboring the bla NDM-5 gene has been described from different human and animal sources in several European countries including Switzerland [ 26 , 27 , 28 ].…”

Section: Resultsmentioning

confidence: 99%

Genomic Characterization of an Extensively Drug-Resistant Extra-Intestinal Pathogenic (ExPEC) Escherichia coli Clinical Isolate Co-Producing Two Carbapenemases and a 16S rRNA Methylase

et al. 2022

View full text Add to dashboard Cite

An extensively drug-resistant Escherichia coli clinical isolate (N1606) belonging to Sequence Type 361 was recovered from the urine of a patient hospitalized in Switzerland. The strain showed resistance to virtually all β-lactams including the latest generation antibiotics cefiderocol and aztreonam–avibactam. Whole genome sequencing revealed that it possessed two carbapenemase-encoding genes, namely blaNDM-5 and blaKPC-3, and a series of additional β-lactamase genes, including blaCTX-M-15 and blaSHV-11 encoding extended-spectrum β-lactamases (ESBLs), blaCMY-145 encoding an AmpC-type cephalosporinase, and blaOXA-1 encoding a narrow-spectrum class D ß-lactamase. Most of these resistance genes were located on plasmids (IncFII-FIA, IncX3, IncIγ, IncFII). That strain exhibited also a four amino-acid insertion in its penicillin-binding protein 3 (PBP3) sequence, namely corresponding to YRIN. Complete genome analysis revealed that this E. coli isolate carried virulence factors (sitA, gad, hra, terC, traT, and cia) and many other non-β-lactam resistance determinants including rmtB, tet(A), dfrA17 (two copies), aadA1, aadA5 (two copies), sul1 (two copies), qacE (two copies), qepA, mdf(A), catA1, erm(B), mph(A), and qnrS1, being susceptible only to tigecycline, colistin and fosfomycin. In conclusion, we described here the phenotypic and genome characteristics of an extensively drug-resistant (XDR) E. coli ST361 being recognized as an emerging clone worldwide.

show abstract

Occurrence of blaCMY-42 on an IncI1 plasmid in multidrug-resistant Escherichia coli from a tertiary referral hospital in India

Cited by 12 publications

References 33 publications

Acquisition of plasmid-mediated cephalosporinase producing Enterobacteriaceae after a travel to the tropics

Acquisition of plasmid-mediated cephalosporinase producing Enterobacteriaceae after a travel to the tropics

Molecular characterization of Carbapenem resistant Escherichia coli recovered from a tertiary hospital in Lebanon

Genomic Characterization of an Extensively Drug-Resistant Extra-Intestinal Pathogenic (ExPEC) Escherichia coli Clinical Isolate Co-Producing Two Carbapenemases and a 16S rRNA Methylase

Contact Info

Product

Resources

About